Search

Displaying results 2431 - 2440 of 5419 in total
  1. Drug

    PSN357

    go.drugbank.com/drugs/DB05044
    Experimental

    PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.

  2. Drug

    Alimemazine

    go.drugbank.com/drugs/DB01246
    ApprovedVet approvedWithdrawn

    A phenothiazine derivative that is used as an antipruritic.

    Categories: Antihistamines for Systemic Use
  3. Drug

    TM30339

    go.drugbank.com/drugs/DB05085
    Experimental

    TM30339 works through the same receptor as the natural satiety hormone, Pancreatic Polypeptide (PP), but TM30339 has improved properties compared with PP.

  4. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary

  5. Drug

    Arsenic trioxide

    go.drugbank.com/drugs/DB01169
    ApprovedInvestigational

    Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic ...

  6. Drug

    Gimeracil

    go.drugbank.com/drugs/DB09257
    ApprovedInvestigational

    It functions by reversibly and selectively blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU [A31408]. … Approved by the European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with [DB03209] and [DB09256] within the commercially available product "Teysuno".

  7. Drug

    Denileukin diftitox

    go.drugbank.com/drugs/DB00004
    ApprovedInvestigational

    approved to treat a human disease in the US. … [A264349, L51254] Denileukin diftitox was originally approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL),[A264339, L51264] making it the first fusion protein cytotoxin

  8. Drug

    Corticorelin

    go.drugbank.com/drugs/DB05394
    Investigational

    It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. … Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.

  9. Drug

    Acitretin

    go.drugbank.com/drugs/DB00459
    ApprovedInvestigational

    An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.

    Categories: Antipsoriatics for Systemic Use
  10. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    to be approved by the FDA. … [A244815] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.